Source file signed link, expires in 15 minutes
Extracted text 18
Page 1
PT Diagnos Laboratorium Utama, Tbk (DGNS) Newsletter Q-2 Update
Page 2
COMPANY GROUP STRUCTURE OVERVIEW
BMHS (Bundamedik) Group of Companies to form the most BMHS value of excellence and visionary medical methodology
comprehensive lifestyle health care provider in Indonesia are imparted as DGNS has been strategically located within
BMHS Business Unit
IVF Diagnostic Lab
Clinics
Established in 2007, PT Diagnos Laboratorium Utama (“DGNS”)
Specialty Emergency Tbk. Is one of the leading clinical laboratories taking part as one
Hospital Response
of the BMHS (Bundamedik Healthcare System) Group companies
which are focusing in delivering high quality clinical diagnostics
services that are consistent, trustworthy and reliable to all
Hospital Pharmacy partners and customers, with strong experience and
management expertise in clinical laboratory. DGNS offer a wide
range of laboratory services that best suites in class facilities and
Dental infrastructure support.
BIC Clinics Clinic
Currently, DGNS have more than 500 types of test in its arsenal
Medical
Tourism Physiotherapy
and operates in more than 30 sites as both Stand Alone
Board
Laboratories and Hospital or Clinical Laboratories, in Sumatera,
Java, Bali and Sulawesi.
Page 3
EXPERIENCED MANAGEMENT TEAM WITH PROVEN TRACK RECORD IN BUSINESS
AND HEALTHCARE INDUSTRY
26 24 27
Years of Experience Years of Experience Years of Experience
dr. Ivan Rizal Sini, MD,FRANZCOG, GDRM, SpOG Nurhadi Yudiyantho dr. Martinus Eliatulo Zega
President Independent
Commissioner Commissioner Commissioner
26 10 16 27
Years of Experience Years of Experience Years of Experience Years of Experience
Mesha Rizal Sini Fergus Richard Reno Bulan Dilly Dwiasri
President Manging Director, Director of Rizal Sini Suhaemi
Director Finance Director Director of Operation
Page 4
EXTENSIVE LIST OF TEST OFFERED WITHIN OUR INTEGRATED LAB ECOSYSTEM
Diagnos Institute
Excellent
Laboratory
Integrated Clinical
Laboratory Ecosystem
Diagnos focusing in delivering high quality clinical
diagnostics services that are consistent, trustworthy and
reliable to all partners and customers.
We offer a wide range integrated laboratory services that
best suites in class facilities and infrastructure support.
Digital 4
Integration
Page 5
GENETICS PRODUCT AS SERVICES UMBRELLA TO CAPTURE FUTURE MEDICINE
OPPORTUNITY
Strong Uptrend on Genomic Testing Volume signaling
a growing demand on Genetic Testing Product
2,405
2,000
1,800 1,670
1,600
1,400
1,200 1,057
1,000
800 660
564 604
600 486
400 306
200
-
2019 2020 2021 2022 2023 2Q 2023 1Q 2024 2Q 2024
Diagnos Genomic is the leading clinical laboratory when it comes to the service of
reproductive genomics testing. Our team is equipped with strong expertise in
assisting patients for reproductive purposes and family planning. DNAnswer serve
as our service umbrella at Diagnos Genomics with the vision of providing quality and
reliable services through all genetic testing. 5
Page 6
DOMESTIC & INTERNATIONAL RECOGNITION ON HOW COMPANY DELIVER CLINICAL LAB SERVICES Quality Management To provide quality services to customers, we continuously to innovate and are currently accredited by : 1. ISO 45001 : For Occupational Health & Safety Management System on Clinical Laboratory Services 2. ISO 15189 : For Clinical Laboratory Competence and Quality 3. ISO 9001 : Quality Management System 4. RS (SNARS 2012) : Diagnos in hospitals 5. ACHS International accreditation : Diagnos in hospitals
Page 7
PT Diagnos Laboratorium Utama, Tbk (DGNS) Growth Strategy
Page 8
EXPANDING EFFICIENTLY THROUGH NETWORK OF LABS
Our Lab Format How we implement our lab format to our strategy?
National Reference
1 Laboratory
2 Independent Lab Routine Lab Tests:
Branches • Sample Collection
• Result Distribution
3 Lab Outlets 1
National Reference Laboratory Specialized Lab Tests:
• Genomics tests
• Headquarter and also independent labs with the • Esoteric tests
most sophisticated lab equipment and center of
esoteric testing and referral test
• Long & Arduous Lab License Registrations Process
• High Initial Capital Expenditure
• Thorough market research & high marketing budget
2
Independent Lab Branches
• Independent labs with standalone lab license, and supply
distribution center for all of the hospital labs in the vicinity
• Need license and moderate capex
• Act as main hub of national lab
3
Lab Outlets / Sample collecting point
• Located in the heart of partner hospital/clinic which operate with
• Private hospitals
the hospital/clinic license
• Public hospitals
• No Lab License Registration required
• GP/specialized clinics
• Low Capital Initial Capital Expenditure 8
• Corporate clinics
• Enable reach to smaller but lot of captive markets
Page 9
VARIETY OF LAB FORMAT TO SUPPORT OUR EXPANSION STRATEGY
DIAGNOS CIPUTAT (STAND ALONE) DIAGNOS DENPASAR (STAND ALONE) DIAGNOS PADANG (STAND ALONE)
DIAGNOS MAKASSAR (STAND ALONE) DIAGNOS BATAM (STAND ALONE) 9
DIAGNOS GENOMICS (OUTLETS)
Page 10
WELL ESTABLISHED PRESENCE ALL OVER INDONESIA IN CAPTURING THE BROAD HEALTHCARE MARKET
OPPORTUNITY IN THE NATION
We expand our footprint across the nation to
cater market needs within various laboratory
test across all segments.
Our Outlet:
• Diagnos RSIA Bunda (Jakarta)
• Diagnos RSU Bunda (Jakarta)
• Diagnos Morula IVF (Jakarta)
• Diagnos BIC1 (Jakarta)
• Diagnos Morula IVF (Margonda)
• Diagnos RSU Citra Harapan (Bekasi)
• Diagnos BIC Vida (Bekasi)
• Diagnos RSIA Citra Ananda (Ciputat)
• Diagnos RS Amanah Mahmudah (Brebes)
• Diagnos RSJP Paramarta (Bandung)
• Diagnos RSIA Bunda (Denpasar)
• Diagnos RSIA Pusura Tegalsari (Surabaya)
• Diagnos RSIA Budhi Mulia (Pekanbaru)
• Diagnos RSIA Az Zahra (Palembang)
• …and many more
10
Page 11
DIGITAL B2B2C PLATFORM TO IMPROVE DOCTOR ENGAGEMENT AND PATIENT CONVERTION ON
LABORATORY TEST ON ALL PARTNERED DOCTOR, CLINIC & HOSPITALS
SIMPLIFIED INDUSTRY SWOT
WEAKNESS
• Uncontested market in the
HIGHLIGHTS :
STRENGTH unpenetrated areas like papua • We Target to launch our Doctor engagement apps by Early 2023
and maluku
• By Digitalizing the doctor engagement process, we could maintain our
OPPORTUNITY THREAT
• Growing adoption of digital • Delay of samples transportation
relation through better customer / partner relationship management
pathology platform which adversely impact TAT
• Digital literacy is higher than
ever
HOW WE PLAN TO TRANSFORM THE CURRENT INDUSTRY VALUE CHAIN IN INDEPENDENT CLINICAL LABORATORY
DOCTOR CLINICAL
PATIENT DOCTOR PATIENT
LABORATORY
CONVENTIONAL
A PATIENT SEEK MEDICAL ATTENTION
DOCTOR REQUIRE LAB
B SERVICE FOR DIAGNOSTICS
LAB SERVE PATIENT & GIVES LAB
C PATIENT LOOKS FOR ANY CLINICAL LABORATORY PROVIDER IN THE PROXIMITY D SERVICES FOR DIAGNOSTICS
F UPON RECEIVING LAB RESULT DOCTORS FINALIZED ITS
E PATIENT RETURN TO DOCTORS BRINGING LAB TEST RESULT DIAGNOSTICS & GIVES MEDICINE
DIGITALIZATION
• Eliminate process C and E
Doctors = mass doctor engagement, informative test options, lab result management, personal assistance
Patients = active sample pickups, personal assistance
11
• Fully automated, transparent calculation on doctor’s benefit
Page 12
Enhancing Our Product Focus AS PART OF OUR MARKET PENETRATION STRATEGIES
in collaboration with DNA and Me
#KenaliDiriKamu
Genetic screening by Diagnos Genomics that can provide
information about personal genetic profile
We are also available at :
12
Page 13
STRATEGIC PARTNERSHIP TO ENHANCE DIGITAL FOOTPRINT IN INDONESIA
CLINICAL LABORATORY INDUSTRY
HOMECARE SERVICES
Partnership with homecare services
specialist allows DGNS to seamlessly PHARMACOGENOMICS & GENOMICS LAB
deliver lab services to each patient houses Supported by Nala Pharmacogenomics
or pre-designated destination allows DGNS to support precision medicine
and able to do risk prediction for its patient
Network of Clinic NUTRIGENOMICS AND MEDICAL CLINICS
Partnered with one of southeast Asia most
ONLINE LAB REFERAL AND OFFLINE emerging biotech startup, DGNS are to
LABORATORIES launch new Nutrigenomics products which
Positioned as exclusive lab partners, DGNS allows online to offline reservation and
are to received online lab test referral and consultations.
to build labs in the KP network of Clinics
13
Page 14
FINANCIAL PERFORMANCE
FY 2023
1Q 2024
2Q 2024
14
Page 15
COMPREHENSIVE DIAGNOS TEST OFFERING DETAILS
DIAGNOS TOTAL TEST OFFERING OVER THE YEAR Key Points
• Genomic contribution to Total Revenue has been increasing
Total Test (x)
in-line with our commercial efforts to push market
awareness, hence, the average YTD 2024 of 18%
contribution from previous year of 15%.
• As of 2Q 2024 we run 25 Outlets across Indonesia, ranging
from Sumatra to Sulawesi region.
DIAGNOS GENOMIC TEST OFFERING OVER THE YEAR
888,033
766,162 2,405
685,701
546,313 1,670
1,057
225,800 205,170
162,540 660 564 604
486
2020 2021 2022 2023 2Q 2023 1Q 2024 2Q 2024 2020 2021 2022 2023 2Q 2023 1Q 2024 2Q 2024
15
Page 16
DIAGNOS OVERALL REVENUE DEVELOPMENT & SOURCES
DIAGNOS Revenue Trend DIAGNOS 2Q 2024 Revenue Breakdown
Total Revenue (IDR Mn)
7.4%
21.4%
302,182
71.2%
183,171 192,886
145,696 41,745 39,300
33,574
2020 2021 2022 2023 2Q 2023 1Q 2024 2Q 2024 Doctor Referrals Corporate Clients
Walk in Customers
16
Page 17
DIAGNOS GROSS PROFIT & NET PROFIT PROFILE
DIAGNOS Gross Profit & Gross Margin DIAGNOS Net Profit & Net Margin
Gross profit Gross Margin Net profit Net Margin ROE *annualized
60.0% 35.0%
49.8% 49.3% 28.8%
47.3% 50.0% 30.0%
41.0% 25.0%
40.0% 21.3%
20.0%
30.0%
15.0%
6.6%
20.0% 5.1% 10.0%
4.2%
10.0% 2.4% 5.0%
1.0%
1.6% (1.1%)
(1.1%) 0.0%
0.0%
(12.7%)
53 64 13 (14) 0.5% 0.9 (5.0%)
(13.8%) (10.0%) (4) 0
87 151 95 60 13 19 17 2020 2021 2022 2023 2Q 1Q 2Q (10.0%)
(20.0%) (9.4%) 2023 2024 2024 (15.0%)
2020 2021 2022 2023 2Q 1Q 2Q
2023 2024 2024 17
(20.0%)
Page 18
Thank You Contact Us Dessy Lapagu (Head of Corporate Finance & Investor Relation) +62817-0877-749 / dessy.lapagu@diagnos.co.id
Names mentioned 6 people and organisations named in the text · linked when the evidence is strong
unresolved
person
dr. Martinus Eliatulo Zega
p.3
Extraction attempts how the parser did, and what it refused
Nothing structured was extracted from this document — the attempts below say why.
No extraction attempted yet.